The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
DETECT III/IV: Two combined clinical trials based on the phenotype of circulating tumor cells (CTCs).
Susanne Albrecht
No relevant relationships to disclose
Fabienne Schochter
No relevant relationships to disclose
Carola Anna Melcher
No relevant relationships to disclose
Carsten Hagenbeck
No relevant relationships to disclose
Thomas W. P. Friedl
No relevant relationships to disclose
Bernadette Jaeger
No relevant relationships to disclose
Brigitte Kathrin Rack
Consultant or Advisory Role - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer; Sanofi
Volkmar Mueller
Consultant or Advisory Role - Amgen; Celgene
Honoraria - Amgen; Celgene; Pierre Fabre Medicament; Roche; Sanofi
Peter A. Fasching
Consultant or Advisory Role - Genomic Health; Novartis; Roche
Honoraria - Genomic Health; Novartis; Roche
Research Funding - Amgen; Novartis
Wolfgang Janni
Consultant or Advisory Role - Lilly; Novartis; Sanofi
Honoraria - Lilly; Sanofi
Research Funding - AstraZeneca; Chugai Pharma; Lilly; Novartis; Pfizer; Sanofi
Tanja N. Fehm
Consultant or Advisory Role - Novartis